Naftali et al.examined a group of 21 subjects, consuming inhaled cannabis with a potency of 23% THC. The study showed that the active treatment group were more likely than patients in the placebo group to decrease their Crohn’s Disease Activity Index (CDAI) score, demonstrating improvement in their condition.
The result, however, was not shown to be statistically significant. In an examination of the current practices of IBD patients, Lal et al. investigated the use of cannabis in a large cohort (n=291) of patients receiving outpatient care. The results showed that of 33% of the patients with ulcerative colitis and 50% of the patient with Crohn’s disease elected to procure and use cannabis to reduce the severity of their symptoms.